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https://doi.org/10.1016/j.celrep.2017.10.010SUMMARY
Genetic alterations impacting ubiquitously expressed
proteins involved in RNA metabolism often result
in neurodegenerative conditions, with increasing
evidence suggesting that translation defects can
contribute to disease. Spinal muscular atrophy (SMA)
is a neuromuscular disease caused by low levels of
SMN protein, whose role in pathogenesis remains un-
clear. Here, we identified in vivo and in vitro translation
defects that are cell autonomousandSMNdependent.
By determining in parallel the in vivo transcriptome
and translatome in SMA mice, we observed a robust
decrease in translation efficiency arising during early
stages of disease. We provide a catalogue of RNAs
with altered translation efficiency, identifying ribo-
some biology and translation as central processes
affected by SMN depletion. This was further sup-
ported by a decrease in the number of ribosomes in
SMA motor neurons in vivo. Overall, our findings sug-
gest ribosome biology as an important, yet largely
overlooked, factor in motor neuron degeneration.
INTRODUCTION
Neurons are highly specialized cells, reliant on precise spatial
and temporal control of translation to maintain their unique anat-
omy and physiology. Local control of protein synthesis allows
neurons to regulate axonal outgrowth and growth cone dy-
namics during development and to control cellular processes
required for maintaining neuronal homeostasis throughout the
lifespan (Jung et al., 2014). It is therefore not surprising that dys-
regulation of translation has been linked to the pathogenesis of
several neurological diseases. For example, genetic studies ofCe
This is an open access article undfamilial and sporadic forms of motor neuron diseases have iden-
tified mutations in genes involved in RNA biology as active con-
tributors to disease pathogenesis (Brinegar and Cooper, 2016;
Cookson, 2016; Renton et al., 2014; Sephton and Yu, 2015). It re-
mains unclear, however, why defects in ubiquitously expressed
components of RNA metabolism lead to defects that are largely
restricted to selected cell populations, and the extent to which
changes in translation play a causative role in neurodegeneration
in vivo remains to be fully determined.
Spinal muscular atrophy (SMA) is the most common genetic
cause of infant mortality (Lefebvre et al., 1995; Lunn and
Wang, 2008), where a loss of lower motor neurons leads to atro-
phy of skeletal muscle. In the most common and severe cases
(type I), onset occurs 6 months of age (Lunn and Wang,
2008). SMA is caused by low levels of full-length survival ofmotor
neuron protein (SMN). Humans have two copies of the gene en-
coding SMN: SMN1 and SMN2. 95% of SMA cases are caused
by homozygous deletion of SMN1. SMN1 and SMN2 are 99.9%
identical, with just one base pair difference (Lorson et al., 1999),
resulting in skipping of exon 7 in 85%–90% of SMN2 tran-
scripts. Without exon 7, the SMN2-derived protein is quickly
degraded, leaving only low levels of functional SMN protein
(Burghes and Beattie, 2009; Tisdale and Pellizzoni, 2015).
Several lines of evidence suggest that SMN protein is involved
in the development and maintenance of motor neuron growth
cones, axon, and neuromuscular junctions (Farrar et al., 2017)
mediated, at least in part, through its role in regulating ubiquitin
homeostasis (Groen and Gillingwater, 2015; Wishart et al.,
2014). In concert with other RNA binding proteins, SMN forms
complexes in the nucleus and cytoplasm of neurons (Donlin-Asp
et al., 2016; Fallini et al., 2012). As such, SMN protein has house-
keeping roles in the assembly of ribonucleoprotein (RNP) com-
plexes, including the U3 snoRNA (Wehner et al., 2002) required
for 18S ribosomal RNA biogenesis (Dragon et al., 2002) and the
small nuclear RNP (snRNP) required for processing of histone
pre-mRNAs (Tisdale et al., 2013). In addition, SMN localizes toll Reports 21, 953–965, October 24, 2017 ª 2017 The Authors. 953
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dendrites, synapses, and axons in vivo and in vitro (Be´chade et al.,
1999; Jablonka et al., 2001;Wishart et al., 2014), where it is part of
messenger RNP (mRNP) complexes with roles inmRNA transport
(So et al., 2016; Zhang et al., 2008). These cellular processes are
tightly linked to local translation, suggesting that SMNmay play a
pivotal role in its regulation. Indeed, SMN has been found to asso-
ciate with polyribosomes in vitro (Sanchez et al., 2013) and in the
rat spinal cord (Be´chade et al., 1999). Moreover, components of
the translation machinery are mislocalized in SMN-depleted cells
(Gabanella et al., 2016), and localization and translation of specific
mRNAs are altered in primary neurons derived from SMA mice
(Fallini et al., 2011, 2016; Rossoll et al., 2003). However, a direct
link between SMN and the regulation of translation in vivo has
not yet been demonstrated.
Here, weusedpolysomal profiling to investigate the role of SMN
in translation in an established mouse model of SMA. We show
that SMN depletion leads to widespread perturbations in transla-
tion, thereby identifying a key role for SMN in translation and ribo-
some biology in vivo.
RESULTS
Polysomal Profiling Reveals Translation Defects in SMA
To test the hypothesis that low levels of SMN lead to defects in
translation in vivo, we performed polysomal profiling on brain,
spinal cord, kidney, and liver harvested from the ‘‘Taiwanese’’
SMA mice (Hsieh-Li et al., 2000; Wishart et al., 2014) at pre-,
early-, and late-symptomatic stages of disease. Since onemajor
challenge in studying neurodegenerative diseases such as SMA
is to distinguish true pathogenic changes—occurring early in
pathogenesis—from downstream cellular phenotypes that
represent later-stage consequences of the disease (Ba¨umer
et al., 2009), we did not include disease end-stage mice, thereby
avoiding secondary, non-specific changes. We performed poly-
somal profiling to gather information about the translation state
in SMA, both in vitro and in vivo. We determined the following un-
der both physiological and diseased conditions: (1) the fraction
of ribosomes engaged on polysomes, revealing the overall level
and efficiency of translation (Brina et al., 2015), (2) the protein co-
sedimentation profile with ribosomes and polysomes (Darnell
et al., 2011; Tiedje et al., 2012), and (3) the transcriptome-wide
analysis of RNAs associated with polysomes (i.e. the transla-
tome, POL-seq) by next-generation sequencing (NGS) (King
and Gerber, 2016) (Figure 1A). Graphical representations of
typical polysome profiles are shown in Figure 1B for brain and
in Figure 1C for spinal cord. The first peak contains free cytosolic
light components (RNPs), and the subsequent peaks include
ribosomal subunits (40S and 60S) and monosomes (80S), all
associated with non-translating particles. The remaining peaks
of the profile represent polysomes, which sediment with high
sucrose concentrations and contain the RNAs associated with
ribosomes.
The cytoplasmic localization of SMN, alongside its known role
in mRNA transport along the axon and its potential association
with both ribosomal proteins (Fuller et al., 2010) and polysomes
(Be´chade et al., 1999; Sanchez et al., 2013), prompted us to
confirm its association with polysomes in vivo, determining the
co-sedimentation profiles of SMN in control and SMA brain954 Cell Reports 21, 953–965, October 24, 2017and spinal cord by immunoblotting (Figures 1D and 1E, respec-
tively). In control mice, we observed co-sedimentation of SMN
with the 40S ribosomal subunit, 80S monosomes, and poly-
somes in brain (Figure 1D) and spinal cord (Figure 1E). To further
study the association of SMN with ribosomes/polysomes, we
determined the co-sedimentation profiles of SMN in the pres-
ence of EDTA, which dissociates ribosomes into small and large
subunits, finding that SMN moved toward lighter fractions (Fig-
ure S1A). Moreover, when a sub-cellular fractionation coupled
to high-salt wash was performed, SMN was found to be tightly
associated to the ribosome fraction (Figure S1B). In SMA mouse
tissue, in addition to an overall reduction in SMN levels, co-sedi-
mentation analysis demonstrated a corresponding decrease of
SMN co-sedimentation with both monosomes and polysomes
(Figures 1D and 1E). Moreover, in SMA spinal cord, SMNmoved
toward lighter fractions that correspond with ribonucleoparticles
(Figure 1E). Thus, cytoplasmic SMN partially co-sediments with
translation machinery in vivo, while in SMA, SMN is depleted
from ribosomal fractions and moves to non-ribosome-associ-
ated fractions.
When comparing polysomal profiles from late-symptomatic
SMA and age-matched control tissue (Figures 1B and 1C), we
noted a reduction in the polysome peak of SMA profiles, sugges-
tive of translation defects. To quantify this effect, we determined
the fraction of ribosomes engaged on polysomes (FRP) at
different stages of disease (Experimental Procedures and Fig-
ures 1F and 1G). This value provides an estimate of the
translation status/activity of tissues and cells, describing
the engagement of ribosomes on RNAs in polysomes and/or
the recruitment of mRNAs on polysomes for translation (Anand
et al., 2003; Brina et al., 2015; Ortiz and Kinzy, 2005). We
compared FRP values in different tissues of SMA mice at
different stages of disease with age-matched controls, finding
no detectable changes at pre-symptomatic stages in any tissue.
Strikingly, however, we observed a strong decrease in FRP in
SMA spinal cord from symptomatic mice (Figure 1G). In addition,
we noted a significant decrease at early- and late-symptomatic
stages in SMA brain (Figure 1F), indicating that translation can
be affected early in the disease process. A decrease in kidney
but no change in liver (Figures S1C–S1E) suggests that transla-
tion defects display tissue specificity, with the most pathologi-
cally affected tissues in SMA showing the greatest magnitude
of change.
To investigate the temporal nature of translation changes, we
compared the extent of translation impairment with established
SMA phenotypic disease readouts: body weight (Hsieh-Li
et al., 2000) and righting time (Le et al., 2005). SMA mice were
easily discernible from control littermates at early- and late-
symptomatic stages, as demonstrated by decreased body
weight and increased righting time (Data S1). In contrast, at
pre-symptomatic stages, SMA and control mice were indistin-
guishable. In control and pre-symptomatic SMA mice, normal
body weight and short righting times were associated with
high FRP values in brain (Figure 1H) and spinal cord (Figure 1I).
In contrast, in early- and late-symptomatic SMA mice, lower
FRP values correspondedwith the appearance of disease symp-
toms. The relationship between lower FRP values and lower rela-
tive weight (Figure 1H and 1I, left panels) and longer time to right
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Figure 1. Translation Is Impaired in Symp-
tomatic SMA Nervous Tissues
(A) Experimental design and analyses using poly-
somal profiles from control (CTRL) and SMAmouse
tissues.
(B and C) Sucrose gradient absorbance profiles
from CTRL and SMA brains and spinal cords (late
symptomatic).
(D and E) Co-sedimentation profiles of SMN and
ribosome markers RPS6 and RPL26 under the
corresponding sucrose gradient. The signal of
SMN along the profile is shown for short (SMN_s)
and long (SMN_l) exposure times of acquisition.
(F and G) Comparison between the fraction of ri-
bosomes in polysomes (FRP) in CTRL and SMA
mouse brains (F) and spinal cords (G) at three
stages of disease (brain: pre-symptomatic, CTLR
n = 4, SMA n = 7; early symptomatic: CTLR n = 6,
SMA n = 6; late symptomatic: CTRL n = 16, SMA
n = 14; spinal cord: pre-symptomatic: CTRL n = 7,
SMA n = 6; early symptomatic: CTLR n = 5, SMA
n = 9; late symptomatic: CTLR n = 7, SMA n = 10,
*p < 0.05, **p < 0.01, ***p < 0.001, two-tailed t test).
(H and I) Relationship between body weight (left) or
righting time (right) and the corresponding FRP,
obtained from CTRL and SMA mouse brains (H)
and spinal cords (I). Each point corresponds to one
mouse. Spearman and Pearson correlations be-
tween are indicated (*p < 0.05, **p < 0.01, ***p <
0.001, correlation test).
See also Figure S1 and Data S1.(Figures 1H and 1I, right panels, and Figures S1E and S1F)
confirmed that translation defects in SMA are associated with
established phenotypic readouts of disease progression. Thus,
FRP values reflect translation defects downstream of SMN
depletion that co-occur with early phenotypic changes in SMA.
Translation Defects Are SMN Dependent
Having demonstrated a decrease in the fraction of ribosomes on
polysomes in SMA and the association of translation impairment
with disease severity, we next wanted to establish whether these
changes were directly dependent upon SMN protein expression.
To assess this, we investigated polysome profiles of SMA mice
treated with an established antisense oligonucleotide (ASO)
that leads to restoration of SMN levels (Hua et al., 2011; Zhou
et al., 2013). Mice received an intravenous injection of a
25-mer morpholino ASO (PMO25) that targets the SMN2 intronCell R7 splicing silencer N1. As expected, this
treatment increased levels of SMN2 exon
7 inclusion in the central nervous system
(CNS) (Zhou et al., 2013). After polysomal
profiling (Figure 2A), we determined the
FRP in brain and spinal cord of control,
SMA, and ASO-treated SMA mice (Fig-
ure 2B). The increase in SMN protein
levels restored SMN on polysomes (Fig-
ure 2C) and robustly rescued disease
symptoms compared with untreated
SMA mice (Figures S2A and S2B). As pre-viously, loss of SMN from polysomes in late-symptomatic SMA
mice was associated with a significantly decreased FRP in brain
and spinal cord compared to littermate controls (Figure 2D). In
contrast, ASO treatment not only restored the amount of SMN
but actually increased levels compared to controls. This resulted
in restoration of the amount of SMN on polysomes and the frac-
tion of ribosomes in polysomes (Figure 2D). Moreover, FRP
values after ASO treatment correlated with normal weight and
righting times (Figures 2E, S2C, and S2D).
Thus, these results demonstrate that translational defects
observed in SMA can be reversed by restoring SMN.
Translation Impairment Is Cell Autonomous
Whether the defects in ribosome engagement on polysomes
detailed above are a major driver of functional impairment of
translation and/or cell autonomous remained to be determined.eports 21, 953–965, October 24, 2017 955
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Figure 2. Treatment with ASO Recovers SMN
Expression and Translation Defects in SMA
Tissues
(A) Experimental design.
(B) Representative polysomal profiles obtained
from brains (top) and spinal cords (bottom) in each
experimental group.
(C) Representative polysomal profiles obtained from
CTRL, SMA, and SMA-ASO mouse brains (late
symptomatic) and corresponding co-sedimentation
profiles from each experimental group for SMN,
RPS6, and RPL26.
(D) FRP from CTRL, late-symptomatic SMA and
SMA-ASO brains (left) and spinal cords (right) (CTRL,
n = 5; SMA, n = 5; ASO, n = 5, *p < 0.05, **p < 0.01,
***p < 0.001, two-tailed t test).
(E) Relationship between body weight (left) or righting
time (right) and the corresponding FRP, obtained
from CTRL, SMA, and ASO-treated mouse brains.
Each point corresponds to one mouse. Spearman
and Pearson correlations are indicated. (*p < 0.05,
**p < 0.01, ***p < 0.001, correlation test).
See also Figure S2.We therefore cultured primary motor neurons (the main
affected neuronal cell type in SMA [Powis and Gillingwater,
2016]) and primary hippocampal neurons (a more modestly
affected cell type [Wishart et al., 2010]) from SMA and control
mice. Wemeasured de novo protein synthesis levels using an es-
tablished metabolic labelling technique based on incorporating
the methionine-homologue L-azidohomoalanine (AHA) into newly
synthesized proteins (Dieterich et al., 2010). When primary motor
neurons were treated with anisomycin, an inhibitor of translation,
the AHA fluorescence signal decreased to background levels
(Figures S3A–S3C) while, when applying AHA metabolic labelling
to primary SMA-derived motor and hippocampal neurons (Fig-
ures 3A and 3B), we observed a marked decrease in fluores-
cence: 37% decrease in SMA versus control motor neuron
cell bodies (Figure 3C). Similarly, fluorescence intensity in axon
segments of primary motor neuron revealed an  39% decrease
(Figure S3D). Comparable quantification in primary hippocampal
neurons indicated a moremodest decrease of21% (Figure 3D).
In line with these results and with previously observed patholog-
ical changes in the hippocampus and cortex of SMA mice (Wish-
art et al., 2010), we found a significant decrease in FRP in
dissected cortex and hippocampus from late-symptomatic
SMA mice, while no changes were detected in the cerebellum
(Figure S3E). These results demonstrate that defects in ribosomal
engagement on polysomes in whole tissues (e.g. spinal cord or
brain) are restricted to specific anatomical regions and cell popu-
lations (e.g., motor and hippocampal neurons), with the most
robust defects in de novo protein synthesis observed in the pri-
mary affected cell type in SMA, the motor neuron.956 Cell Reports 21, 953–965, October 24, 2017Next, to study the role of SMN in inducing
the observed translation defects, we devel-
oped motor-neuron-like cell lines (NSC-34)
expressing SMN at defined levels using
CRISPR/Cas9 technology. We isolated
and expanded clones expressing 20% and0% SMN (Figure 3E) and performed polysome profiling (Fig-
ure 3F) to determine the FRP. As seen in whole tissues, we
observed translation defects that correlated directly with the
relative level of SMN loss (Figure 3G).
Taken together, these data suggest that translation impair-
ment is a cell-autonomous event in SMA that is regulated directly
by SMN levels.
Determining the In Vivo SMA Transcriptome and
Translatome by Next-Generation Sequencing
Weused next-generation sequencing (NGS) to identify and quan-
tify, in parallel, the total cytoplasmic RNA (RNA-seq) and the
RNAs associated with polysomes (POL-seq). We extracted total
cytoplasmic and polysomal RNAs from pooled sucrose fractions
from control, early-, and late-symptomatic SMA mice (Figure 4A)
to simultaneously identify variations in RNA populations at both
translatome (RNAs engaged with polysomes) and transcriptome
(steady-state cytoplasmic RNAs) levels (Data S2). Transcriptome
and translatome changes were moderately correlated, with an
overlap of approximately one-third between differentially ex-
pressed genes (DEGs, 27% in early-symptomatic, 39% in late-
symptomatic mice, see Figure S4A). To confirm the data, we
chose a set of nine differentially expressed genes across early-
and late-symptomatic stages for validation by qPCR. We found
a high concordance between the NGS and qPCR approaches
at both stages (r2 =0.77 for early-symptomatic stage and
r2 =0.99 for late-symptomatic stage [Figure S4B]).
To understand whether variations identified at early- and late-
symptomatic stages and at translational and transcriptional
A B C D
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Figure 3. Translation Defects are Cell Autonomous and Dependent on SMN Loss
(A and B) Primary motor neurons (A) and primary hippocampal neurons (B) from control and SMA embryos were stained to reveal overall morphology (beta-III-
tubulin, red) and nuclear integrity (DAPI, blue). Protein synthesis was visualized by labelling newly synthesized proteins with L-azidohomoalanine (AHA, gray
scale, scale bars: 50 mm (overview), 10 mm (cell bodies; beta-III-tubulin/DAPI and AHA). DAPI, 4’,6-diamindion-2-phenylindole).
(C) AHA fluorescence intensity values in individual primary motor neurons in three independent preparations: SMA (n = 43, 41, and 56) and control (n = 42, 40,
and 56).
(D) AHA fluorescence intensity values in individual primary hippocampal neurons in three independent preparations: SMA (n = 29, 50, and 48) and control (n = 20,
48, and 32) (**p < 0.01, *p < 0.05, Student’s t test; error bars ± SEM.).
(E) SMN levels in NSC-34 native (CTRL), the pool of cells expressing different levels of SMN (POOL), and two specific clones expressing 20% and 0% of SMN.
(F) Representative polysomal profiles from NSC-34 native (CTRL) and the two clones expressing 20% and 0% of SMN. Co-sedimentation profiles of SMN and
RPL26 are shown. The signal of SMN is shown for short (SMN_s) and long (SMN_l) exposure times of acquisition.
(G) Comparison between the FRP in NSC-34 native and expressing 20% and 0% of SMN (CTRL: n = 3; 20%: n = 3; 0%: n = 3). Significant decreases were
identified with one-tailed t test (**p < 0.01).
See also Figure S3.levels were also hallmarks of pre-symptomatic disease stages,
we determined an expression time course for transcripts
changed at both levels previously selected for qPCR validation(Figure S4C).We found that some transcripts were already differ-
entially expressed at pre-symptomatic stages, indicating early
pathogenic changes. Next, we determined the expression ofCell Reports 21, 953–965, October 24, 2017 957
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the same set of transcripts in RNA isolated from spinal cord.
Most changes could be detected not only in brain but also in spi-
nal cord (Figure S4D). Moreover, these changes were reversible,
as ASO treatment that restored SMN levels (Figure 2) normalized
the expression at both levels (Figure S4E). Finally, to confirm that
at least some of the changes identified in SMA on polysomes
resulted in corresponding changes at the protein level, we
measured levels of UBA6 and RGS5. Both proteins showed a
decrease in expression that matched changes at the RNA level
(Figure S5). Thus, transcripts identified as differentially ex-
pressed in SMA by RNA-seq and POL-seq reflect early changes
during disease progression, including variations in the spinal
cord and at the protein level. Moreover, these changes are
reversible by ASO treatment restoring SMN expression.
Alterations in Translation Efficiency Highlight Defects in
Ribosome Biology in SMA
Having determined, in parallel, the transcriptome (RNA-seq) and
translatome (POL-seq), we next calculated the ratio between
POL-seq and RNA-seq data for each transcript, exploring
changes in the equilibrium between transcription and translation
in SMA. This approach also allowed us to obtain a transcrip-
tome-wide profile of individual genes that were affected by the
widespread translation defects we reported above. We gener-
ated a comprehensive catalogue of changes in translation effi-
ciencies (TEs) (Tebaldi et al., 2014; Xiao et al., 2016) of individual
coding and non-coding RNA transcripts in control and SMA tis-
sue at both early- and late-symptomatic stages (Figure 4B and
Data S3). This catalogue comprises 470 and 442 transcripts
with significantly altered TE at early- and late-symptomatic
stages, respectively. Interestingly, most RNAs with altered TE
are protein coding, but a small fraction of these RNAs is noncod-
ing (Figure 4C). Genes with significantly altered TE were mostly
different from DEGs identified from the separated analysis of
transcriptome and translatome variations (Figure S4F).
To gain insight into the molecular processes affected by
changes in TE, we performed Gene Ontology and pathway
enrichment analyses on transcripts with altered TE values (Fig-
ure 4D and Data S3). When focusing on transcripts with reduced
levels of TE at early stages of disease, two major cellular pro-
cesses emerged: nucleosome/chromatin and ribosome/transla-
tion. Interestingly, however, the ribosome/translation category
was the only one robustly conserved at the late stage (Figure 4D).
This suggests that defects in ribosome/translation are an early
event following SMN depletion that persist into late stages of
SMA. Notably, enrichment of translation/ribosome terms was
also specific for translatome DEGs in early symptomatic mice
(Figure S4G). This suggests that TE variations for these genesFigure 4. Identification of RNAs with Defective Translation Efficiency R
(A) Experimental design for POL-seq and RNA-seq profiling on brains from late s
(B) Volcano plot displaying translation efficiency variations (x axis) and associated
brains compared to controls. Genes with statistically significant variations in TE
regulation in SMA.
(C) RNA subtypes of genes with significantly altered TE in early- (top) and late-sy
(D) Heatmap with top enriched terms (from Gene Ontology) and pathways (from
significant changes of TE in early- and late-symptomatic SMA brains. The numb
See also Figure S4 and Data S2 and S3.are primarily driven by changes in their polysomal RNA levels
in early symptomatic mice.
A large majority of transcripts with a significantly reduced TE
and associated with ‘‘translation’’-related processes were ribo-
somal proteins, translation initiation and elongation factors,
and proteins involved in ribosome biogenesis (Figure 5A). We
quantified individual transcript levels for 14 ribosomal genes
and one translation factor by qPCR and confirmed that the
expression of numerous transcripts involved in ribosome
biogenesis (Jakovljevic et al., 2012; Landowski et al., 2013; Lo
et al., 2009) is affected in SMA, both at early- and late-symptom-
atic stages (Figure 5B). Moreover, western blot analysis
confirmed that reduced TE of ribosomal proteins RPS4X and
RPS6 leads to reduced protein levels at late-symptomatic stages
(Figure S5), in line with our hypothesis that defects in ribosome
abundance could underlie the decreased FRP (Figure 1) and
other translation defects observed in SMA.
Finally, to establish whether downregulation of translation-
related transcripts leads to downstream functional changes in
ribosome biology in vivo, we performed ultrastructural analyses
of ribosomes in motor axon profiles from intercostal nerves iso-
lated from symptomatic severe SMA mice and littermate con-
trols (Hunter et al., 2016). As expected, transmission electron
microscopy revealed prominent axonal ribosomes in both con-
trol and SMAmice (Figure 5C). Importantly, quantitative analyses
of axonal ribosomal density revealed a 27% decrease in the
number of axonal ribosomes in intercostal nerves from SMA
mice versus controls (Figure 5D).
Thus, cellular processes identified through genome-wide
analysis of TE in SMA allowed us to pinpoint hallmarks of SMA
in vivo, demonstrating that SMN plays a role in translation and
ribosome biology.
DISCUSSION
Increasing evidence suggests a role for translation defects in the
pathogenesis of neurodegenerative diseases. Ribosomal de-
fects have been documented in conditions such as Alzheimer’s
disease, Huntington’s disease, Parkinson’s disease, and fronto-
temporal dementia (Ding et al., 2005; Lee et al., 2011; Vilotti et al.,
2012). Here, we found that SMN protein is an important mediator
of translation in the nervous system during SMA.We employed a
range of methods to reveal a role for SMN in regulating transla-
tion in vitro and in vivo, using NGS to determine widespread
changes occurring in the translatome in SMA and to generate
a unique catalogue of RNAs with altered translation efficiency.
We established that SMN depletion leads to an early and robust
impairment of translation-related transcripts in SMA and toeveals Functional Clusters of RNAs with Altered Translation in SMA
ymptomatic SMA and control mice.
p values (y axis) in early symptomatic (top) and late symptomatic (bottom) SMA
are labelled according to the direction of the change: up (blue) or down (red)
mptomatic (bottom) SMA mice.
KEGG and Reactome). Enrichment analysis was performed on genes with
er of genes contributing to the enrichment is indicated in each tile.
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A B
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Figure 5. Translation Alterations in SMA Reveal Links between SMN and Ribosome Biology
(A) Heatmap displaying all genes with altered translation efficiency (DTE) in SMA brains and annotated under the ‘‘Translation’’ Reactome pathway, significantly
enriched in Figure 4D. The majority of genes belong to the family of ribosomal proteins. Genes further analyzed by qPCR are highlighted in black.
(B) qPCR-derived variations of translation efficiency for ribosomal proteins and one elongation factor from (A) in early (top) and late (bottom) symptomatic mouse
brains. Mean value ± SEM is shown; three to four biological replicates and two to six technical replicates; all genes were normalized to the geometric mean of
actin and cyclophilin a; one-tailed t test; *p < 0.05, **p < 0.01, ***p < 0.001.
(C) Representative electron micrograph of a large diameter (motor) axon in the intercostal nerve from a P5 SMA mouse (black arrowheads: axonal ribosomes;
white arrowhead, ER ribosomes).
(D) Counts of axonal ribosomes revealed a decrease in the density of ribosomes in SMAmouse axons compared to controls (n = 30 axon profiles; N = 3 mice per
genotype; ***p < 0.001, two-tailed t test).
See also Figure S5.
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consequent defects in ribosomal biology. In addition, we
demonstrated that translation defects are cell autonomous and
can be rescued by therapies increasing SMN protein levels, sug-
gesting that defects in translation and ribosome biology are core
pathological hallmarks of SMA. In this context, our findings pro-
vide in vivo evidence supporting the hypothesized physiological
role of SMN in the localization of the translation machinery and
translation of specific transcripts proposed previously by
in vitro studies (Fallini et al., 2011, 2016; Gabanella et al., 2016;
Sanchez et al., 2013).
One longstanding issue in several neurodegenerative dis-
eases is the lack of a robust explanation for the cell-type
specificity that results from defects in ubiquitously expressed
proteins. Indeed, this is also a feature of SMA following ubiqui-
tous depletion of SMN protein (Hamilton and Gillingwater,
2013). Although spinal motor neurons are the most prominently
affected cell type, numerous other cell types and tissues can
also be affected in SMA, both in patients and animal models
(e.g., Shababi et al., 2010; Somers et al., 2016). Translation de-
fects we report here were notably most pronounced in brain
and spinal cord, with more modest defects observed in kidney
and no defects in the liver. These findings support a threshold
model for the requirement of SMN, where different tissues
and cell types require different minimal levels of SMN and are
thus differentially susceptible to reduced levels of SMN (Sleigh
et al., 2011). Our catalogue of RNA defects suggests that
translation and ribosome biology are major downstream medi-
ators of the effects of low levels of SMN across different tissues
in SMA.
Interestingly, our parallel transcriptome and translatome ana-
lyses revealed that one-third of the transcriptional changes that
occur in SMA are directly reflected in translation changes of
the same transcripts. Indeed, large changes in the transcriptome
driven by alterations in functional translation or ribosome
biogenesis can be primarily caused by feedback mechanisms
at the transcriptional level (Santagata et al., 2013), pointing to-
ward translation as possible primum movens of transcriptional
changes. The fact that altered splicing alone cannot explain
SMA pathogenesis (Ba¨umer et al., 2009; Shpargel and Matera,
2005) and that very few transcriptional changes have been
detected in pre-symptomatic SMA tissues (Doktor et al., 2016)
emphasizes that SMA pathogenesis is likely to be multifactorial.
Therefore, further hypotheses are required to better understand
the complex mechanistic role of SMN in controlling RNA
metabolism in the cytoplasm, especially with respect to the
translation machinery in general. Given the well-known nuclear
role of SMN, it is tempting to speculate that SMN may coordi-
nate, together with other proteins, the fine equilibrium between
RNA synthesis, nuclear export, transport, translation, and ribo-
some biogenesis, whose balance is likely to be particularly crit-
ical for neurons. In agreement with this hypothesis, SMN can
localize to the nucleolus, where it interacts with U3 snoRNA
involved in processing of ribosomal RNA (rRNA) (Wehner et al.,
2002). Among the lncRNAs showing defects in SMA, several
were found to associate with polysomes, supporting the hypoth-
esis that lncRNAs are likely to influence the activity of polysomes
(Carlevaro-Fita et al., 2016; Ingolia et al., 2011). Interestingly,
among those RNAs with altered TE, we identified severalsnoRNAs involved in ribosome biogenesis. Similarly, the charac-
terization of the SMN interactome identified likely interactions
between the SMN complex and numerous ribosomal proteins,
as well as the translation elongation factor eEF1A1 (Fuller
et al., 2010). It is possible, therefore, that low levels of SMN
impact the proper production of ribosomes in SMA, especially
in the most affected cells and tissues. Interestingly, a recent
study showed that ribosomeswith different subsets of ribosomal
proteins control pools of mRNAs with specific functions in
mESCs (Shi et al., 2017). This raises another intriguing hypothe-
sis: SMN might induce, indirectly or directly, changes in the
ribo-proteome, impacting specialized ribosomes and changing
their selectivity for translational regulation of subpopulations of
axonal-specific mRNAs.
Taken together with findings from other neurodegenerative
conditions, our study adds experimental weight to the hypoth-
esis that translation represents a common molecular ‘‘hub’’ in
disease pathogenesis. Indeed, recent studies of amyotrophic
lateral sclerosis (ALS) have highlighted a role for translation
defects. For example, one major pathological protein in ALS,
TDP43, has been shown to regulate the translation of specific
transcripts (Coyne et al., 2014). Similarly, ALS-associated
protein aggregates affect the function of proteins that play
an important role in regulating translation, such as FMRP (Blo-
khuis et al., 2016; Coyne et al., 2015), and mislocalization of
axonal ribosomes occurs in ALS patients (Verheijen et al.,
2014). It is interesting to note that many proteins that have
been implicated in regulating translation and are associated
with neurodegenerative diseases contribute to larger RNA-
protein complexes (Blokhuis et al., 2016; Groen et al., 2013;
Liu-Yesucevitz et al., 2011; Piazzon et al., 2008). This compli-
cates the process of separating causative from secondary
changes in disease, as likely functional redundancy in these
complexes makes it challenging to detail true pathogenic
changes. The use of powerful emerging technologies facili-
tating genetic tagging of ribosomes in vivo (e.g., Shigeoka
et al., 2016), will likely play a major role in future investigations
of the role of ribosome biology in motor neuron diseases such
as SMA and ALS.EXPERIMENTAL PROCEDURES
Animal Models and ASO Treatment
‘‘Taiwanese’’ (Smn/; SMN2tg/0) severe SMA mice (Powis and Gilling-
water, 2016) on a congenic FVB background were generated from breeding
pairs originally purchased from Jackson Labs. Phenotypically normal het-
erozygous (Smn/+;SMN2tg/0) littermates were used as controls. For EM
experiments, tissue had been banked from a ‘‘severe’’ SMA mouse colony
(Hunter et al., 2014). Litters were genotyped using standard PCR protocols.
Mice were housed in Edinburgh and UCL (London) under standard SPF
conditions. All animal procedures and breeding were in accordance with
University of Edinburgh and UCL institutional guidelines and under appro-
priate project and personal licenses granted by the UK Home Office.
ASO treatment was performed at UCL as previously described (Zhou et al.,
2013). Disease progression of transgenic mice can vary between laboratories
(Casellas, 2011). We therefore refer to time points at which tissue was
collected as pre-, early- and late-symptomatic (Edinburgh: pre-symptomatic,
P3; early symptomatic, P5; and late symptomatic, P7). Tissue from UCL was
from late-symptomatic (P10) mice that were phenotypically similar to P7
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Motor Performance Test
Mice were weighed daily. Motor performance was recorded using the righting
reflex test (Passini et al., 2010; Wishart et al., 2014). Righting tests were per-
formed in triplicate for each mouse and an average time calculated. If a mouse
took longer than 30 s to right, the test was terminated.
Tissue Isolation
Neonatal mice were euthanized by overdose of anesthetic before decapitation
to remove the brain. Spinal cord dissection was performed by removing the
spinal column and then using a needle and syringe to flush out the intact
cord (Powis and Gillingwater, 2016). Peripheral tissues (kidney and liver)
were subsequently dissected. All tissues were immediately snap-frozen on
dry ice and stored at 80C.
Primary Neuronal Cultures
Primary motor neurons and hippocampal neurons were cultured as described
previously (Van Battum et al., 2014; Blokhuis et al., 2016). All primary cultures
were grown in an incubator at 37C and 5% CO2.
Labeling of Newly Synthesized Proteins in Primary Neurons
Novel protein synthesis was quantified using L-azidohomoalanine (AHA) and
the Click-IT AHA kit (ThermoFisher Scientific) according tomanufacturer’s rec-
ommendations. After 7 days in culture, cells were washed with PBS, and the
medium was replaced with methionine-free medium, supplemented with
B27, Glutamax, and AHA for 30 min. Cells were fixed in 4% PFA and permea-
bilized in 0.5% triton-X100 in PBS. The subsequent labelling of newly synthe-
sized proteins was performed using Alexa Fluor 488. Nuclei were stained with
DAPI. Cells were imaged on a Zeiss LSM710 confocal microscope, with iden-
tical settings used within each experiment. Images were analyzed in FIJI; the
cell body was manually delineated and the mean fluorescence intensity
measured. All analyses were performed with the operator blind to the geno-
type or treatment. For control experiments, neurons were pre-treated with
40 mM anisomycin for 30 min.
Polysome Profiling
Cytoplasmic lysates from frozen mouse tissues were prepared as described
previously (Lunelli et al., 2016). Cleared supernatants were loaded on a linear
15%–50% sucrose gradient and ultracentrifuged in a SW41Ti rotor (Beckman)
for 1 hr and 40 min at 180,000 g at 4C in a Beckman Optima LE-80K Ultracen-
trifuge. After ultracentrifugation, gradients were fractionated in 1 mL volume
fractions with continuous monitoring absorbance at 254 nm using an ISCO
UA-6 UV detector.
Protein Extraction and Western Blot
Proteins were extracted from each sucrose fraction of the profile using the
methanol/chloroformprotocol (Wessel and Fl€ugge, 1984) and solubilized in elec-
trophoresis sample buffer (Santa Cruz Biotechnology) for the following SDS-
PAGE and western blot analysis. SDS-PAGE was performed in a 12% gel or a
4%–12%gradientgel (Novex) andblottedonnitrocelluloseorPVDFmembranes.
Western blots were performed using primary antibodies against RPL26 (1:2,000,
Abcam), RPS6 (1:1,000,Cell Signalling), SMN (1:1,000, BDTransductionLabora-
tories), and theappropriatehorseradishperoxidase (HRP) conjugatedsecondary
antibodies (1:5,000, Santa Cruz Biotechnology) or the IRDye secondary anti-
bodies (LICOR). Detectionwas performed using the ECL PrimeWestern Blotting
Detection Reagent (Amersham) or when using infrared secondary antibodies,
scanned on an Odyssey imager (LICOR) (Eaton et al., 2013).
Fraction of Ribosomes on Polysomes
TheFRPwascalculated frompolysomalprofilesas the ratiobetween theareaun-
der the curve of polysomes and the area under the curve of polysomes plus the
areaof the 80Speak. At least threedifferent polysomal profiles (min 3 –max9) for
each tissue (spinal cord or brain), physiological condition (heterozygous control
or SMA), and disease stage (pre-, early or late symptomatic) were considered.
Total and Polysomal RNA and Library Preparation
RNA was extracted from control and SMA brains, from ASO brains, and from
control and SMA spinal cords according to Tebaldi et al. (2012). Profile frac-962 Cell Reports 21, 953–965, October 24, 2017tions (total RNA) or polysomal fractions only (polysomal RNA) were pooled
together. cDNA libraries were produced from 500 ng using the TruSeq
Stranded Total RNA (Illumina) kit according to manufacturer’s instructions.
NGS Data Analysis
RNA-seq and POL-seq sequencing were performed with an Illumina HiSeq
2000 (Mus musculus, GPL13112). Fastq files were checked for quality control
with FastQC. 100 bp reads generated from each sample were aligned to the
mouse genome (GRCm38.p4) with Tophat (version 2.0.14), using the Gencode
M6 transcript annotation as transcriptome guide. All programs were used with
default settings. Mapped reads (ranging from 84% to 92% of total reads, Data
S2) were assembled into transcripts guided by reference annotation (Gencode
M6) with Cufflinks (version 2.2.1). Expression levels were quantified by Cuf-
flinks with normalized FPKM (fragments per kilobase of exon per million
mapped fragments). Differentially expressed genes and transcripts in
RNA-seq and POL-seq samples were detected with CuffDiff (p < 0.05). Trans-
lation efficiency analysis was performed with Xtail (Xiao et al., 2016), and genes
showing differential translation efficiency values were selected using a
threshold on Xtail p value (< 0.05). Functional annotation of gene lists and
enrichment analysis with Gene Ontology terms and KEGG or REACTOME
pathways were performed with the clusterProfiler Bioconductor package.
qPCR
The retrotranscription reaction was performed starting from 1 mg of RNA using
the RevertAid First Strand cDNA synthesis kit (Thermo Scientific). qPCR was
carried out using the CFX Connect Real-Time PCR Detection System (BioRad)
using Kapa Syber Fast qPCR Mastermix (Kapa Biosystems). Primer se-
quences are provided in Data S4. Actin and cyclophilin A were used as refer-
ence genes. All reactions were performed in two to four biological replicates
and two to six technical replicates. The obtained Ct values were used to calcu-
late the fold change of each gene using the delta/delta Ct method (Livak and
Schmittgen, 2001). The log2 delta TE was calculated as the difference be-
tween the fold change at the polysomal level and the fold change at the total
level of the gene of interest.
Electron Microscopy
Tissue was prepared, processed, and imaged using transmission electron mi-
croscopy, as described previously (Hunter et al., 2014).
CRISPR/Cas9 Knockout NSC-34 Cells
Stable SMN knockout in NSC-34 cells was generated by CRISPR/Cas9 tech-
nology. NSC-34 motor neuron-like cell line was grown in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen), 10% FBS (GIBCO, Life Technologies),
2 mM L-Glutamine (GIBCO, Life Technologies), and 1% penicillin/strepto-
mycin (GIBCO, Life Technologies) at 37C in a 5% CO2 atmosphere. RNA
guides were designed to target the exon 3 of mSMN (50 CACCGAGTTGTGG
CATTCTTCTTT 30) and cloned in pX330-U6-Chimeric_BB-CBh-hSpCas9
plasmid (a gift from F. Zhang, Addgene plasmid 42230) implemented with a
puromycin resistance gene (Cong et al., 2013). Cells were transfected using
Lipofectamine 2000 (Life Technologies. Cells were selected using 5 mg/ml
puromycin for 48 hr and clonal expanded. SMN expression levels were
assessed by western blot.
Statistical Methods
For hierarchical clustering based on FRP, relative weight and relative righting
time data were first rescaled in order for each variable to have the same
mean and standard deviation. The distance matrix was calculated with the
‘‘Euclidean’’ method. Clustering was performed with the ‘‘Ward.D’’ agglomer-
ation method. Shifts in distribution mean values were tested with Student’s
t test. All other statistical analyses were performed in Graphpad Prism, with in-
dividual statistical tests used indicated in the figure legends.
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